Print Issue: August 01, 2011

Dual Regimen Benefits Obese Patients

NEW ORLEANS—The combination of sustained-release naltrexone and bupropion leads to sustained clinically meaningful weight loss and improves markers of cardiovascular risk in obese patients, according to results released at the 60th Annual Scientific Session of the American College of Cardiology.

Next post in Cardiovascular Disease (CVD)